The two-year-old Netherlands-based company, arGEN-X BV, has received a €1.5 million grant to accelerate preclinical development of an antibody that targets interleukin 6 (IL-6), a cytokine that plays a role in autoimmune indications. ---Subscribe to MedNous to access this article--- Company News Finance, Grants, Deals
